News & Features

The world of MS information changes rapidly. Breakthroughs in understanding the mechanisms of MS, its cause, and its treatment come at a rapid pace. And there's so much to know just about managing the disease in your daily life! 

To keep you informed and up-to-date, MS Focus offers informative periodicals and round-the-clock multimedia broadcasting. Whether print or digital, these materials are designed to be easy to understand for MS patients, their families, and care providers. Subscriptions are free of charge.

Study shows promise in repairing damaged myelin

April 19, 2019

Discovery, if proven in clinical trials, would offer myelin repair with minimal side effects and efficient delivery.
Learn more

Vitamin D study sheds light on immune system effects

April 18, 2019

This discovery might explain how vitamin D regulates immune reactions that have been implicated in MS.
Learn more

Body mass index may play a role in MS progression

April 15, 2019

Bad dietary habits may have pronounced deleterious effect on patients with MS
Learn more

Study of MS patients shows 18 percent misdiagnosed

April 09, 2019

Researchers hope that the results of this study will help improve diagnostic procedures
Learn more

Study shows no link between minerals and MS risk

April 05, 2019

The minerals studied were zinc, iron, potassium, magnesium, calcium, phosphorus, manganese, and copper.
Learn more

Dose-finding study in relapsing MS seeks participants

March 29, 2019

Sanofi Genzyme is seeking recruits for a Phase II clinical trial.
Learn more

FDA approves Mavenclad, new oral drug to treat MS

March 29, 2019

FDA approves Mavenclad (cladribine) to treat relapsing MS
Learn more

FDA approves Mayzent, new oral drug to treat MS

March 27, 2019

FDA approves Mayzent, a new oral drug to treat relapsing MS.
Learn more

BMI, but not age at puberty, tied to MS risk

March 22, 2019

If so, this could be another important reason for public health initiatives to focus on lowering obesity rates.
Learn more

Study shows promise in repairing damaged myelin

April 19, 2019

Discovery, if proven in clinical trials, would offer myelin repair with minimal side effects and efficient delivery.
Learn more

Vitamin D study sheds light on immune system effects

April 18, 2019

This discovery might explain how vitamin D regulates immune reactions that have been implicated in MS.
Learn more

Body mass index may play a role in MS progression

April 15, 2019

Bad dietary habits may have pronounced deleterious effect on patients with MS
Learn more

Study of MS patients shows 18 percent misdiagnosed

April 09, 2019

Researchers hope that the results of this study will help improve diagnostic procedures
Learn more

Study shows no link between minerals and MS risk

April 05, 2019

The minerals studied were zinc, iron, potassium, magnesium, calcium, phosphorus, manganese, and copper.
Learn more

Dose-finding study in relapsing MS seeks participants

March 29, 2019

Sanofi Genzyme is seeking recruits for a Phase II clinical trial.
Learn more

FDA approves Mavenclad, new oral drug to treat MS

March 29, 2019

FDA approves Mavenclad (cladribine) to treat relapsing MS
Learn more

FDA approves Mayzent, new oral drug to treat MS

March 27, 2019

FDA approves Mayzent, a new oral drug to treat relapsing MS.
Learn more

BMI, but not age at puberty, tied to MS risk

March 22, 2019

If so, this could be another important reason for public health initiatives to focus on lowering obesity rates.
Learn more

Study: MS may not worsen after pregnancy after all

March 18, 2019

Researchers said this shows that women with MS today can have children, breastfeed and resume their treatment without experiencing an increased risk of relapses during the postpartum period.
Learn more

Noncontrast MRI is effective in monitoring MS patients

March 14, 2019

The findings support the possibility that contrast enhancement can be omitted from routine follow-up scans.
Learn more

Soda, sugar-sweetened drinks linked to more severe MS symptoms

March 12, 2019

The study found that participants who consumed the largest amounts of sugar-sweetened beverages were five times more likely to have severe disability than people who seldom drank sugar-sweetened beverages.
Learn more

Cocoa may help curb fatigue typically associated with MS

March 08, 2019

Researchers suggest cocoa may offer an easy, safe approach to the persistent symptom, if confirmed.
Learn more

Researchers identify how metabolites target T cells to treat MS

March 01, 2019

The discovery could lead to novel, more specific, and more effective MS therapies.
Learn more

Study links MS disability progression to income, education

February 27, 2019

The findings paint a clearer picture of the way that wealth and education might affect patients with MS.
Learn more

Study: Chloroindazole compounds show promise as treatments 

February 25, 2019

New compounds offer the protective effects of estrogen without the unpleasant side effects
Learn more

Study finds food allergies and MS link

February 22, 2019

This link between food allergies and MS disease activity highlights an important role of the gut.
Learn more

Regulating the MS-causing properties of Th17 cells

February 19, 2019

A new study identifies a protein regulator responsible for inducing the pathogenic properties of Th17 cells, leading to multiple sclerosis. A research team from Osaka University found that the protein Satb1 triggers a shift in immune cells, causing tissue inflammation and autoimmunity. This breakthrough could lead to new treatments targeting the source of inflammation.

Interleukin 17-producing T-helper cells are a recently-identified class of immune cells that play a major role in protection against invading pathogens. Studies have shown that excessive inflammation induced by Th17 cells is actually one of the underlying causes of many inflammatory and autoimmune disorders. But what causes Th17 cells to cross the line from helpful to harmful? To answer this question, the researchers examined genome organizer protein Satb1.

Using a mouse model of MS, the researchers deleted the Satb1 gene in Th17 cells and found that the disease no longer developed in the mice. Key to this mechanism was the lack of expression of a protein called granulocyte-macrophage colony-stimulating factor by the Satb1-defective Th17 cells. GM-CSF is a pathogenic cytokine that causes localized tissue inflammation in MS. Satb1 was also found to enhance the expression of the GM-CSF gene, confirming its role in promoting inflammation.

Satb1 also blocks the expression of a protein specially designed to suppress T-cell inflammatory activity and prevent autoimmune diseases. This protein, programmed cell death protein 1, was more highly expressed in Satb1-deficient Th17 cells compared with normal Th17 cells, indicating that Satb1 normally inhibits protein expression.

Results of mouse model studies sometimes do not translate to humans and may be years away from being a marketable treatment. However, the researchers said the results suggest that manipulating Satb1 gene expression in Th17 cells could form the basis of novel treatments for various autoimmune diseases caused by Th17 cells. If they can prevent the pathogenic processes of Th17 cells, they may be able to alleviate or even eliminate disease symptoms.

The study was published in Nature Communications.
Learn more


Show More News